High-dose carboplatin plus paclitaxel with granulocyte colony-stimulating factor and peripheral blood stem-cell support in non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 40, Issue , 1997, Pages

  Shea, T C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; NSCLC; Paclitaxel; Stem cells

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; DOCETAXEL; EDATREXATE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; TOPOTECAN;

CANCER STAGING; CONFERENCE PAPER; DOSE RESPONSE; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

EID: 0030741152     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051066     Document Type: Conference Paper

References (44)

1. Anderson H, Lund B, Hansen HH, Walling J, Thatcher N (1991) A phase II trial of gemcitabine in non-small-cell lung cancer. Proc Am Soc Clin Oncol 10:247 (abstract)
2. Belli L, Le Chevalier T, Gottfried M, Adams D, Ruffé P, Le Cesne A, Tete L, Pellae-Cosset B (1995) Phase I-II trial of paclitaxel and cisplatin in previously untreated advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 14:350 (abstract)
3. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MC, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Click J (1989) Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602
4. Bonomi P, Kim K, Chang A, Johnson D (1996) Phase III trial comparing etoposide-cisplatin versus taxol with cispIatin-G-CSF versus taxol-cisplatin in advanced non-small-cell lung cancer. An Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol 15:382 (abstract)
5. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748
6. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D (1993) Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388
7. Crawford J, O'Rourke M, Schiller JH, Spiridonitis CH, Yanovich S, Ozer H, Langeben A, Hutchins L, Koletsky A, Clamon G, Burman S, White R, Hohneker J (1996) Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 14:2774
8. DePierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dolphin JC (1991) A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 14:115
9. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF, Green MR (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940
10. Fennelly D, McKenzie M, Spriggs D, Aghajanian C, Shapiro F, O'Connor C, O'Flaherty C, Barakat R, Curtin J, Hoskins W (1996) Rapidly sequenced high-dose paclitaxel plus carboplatin followed by melphalan: a phase I feasibility study in patients with advanced ovarian cancer. Proc Am Soc Clin Oncol 15:339 (abstract)
11. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Hong WK, Raber M (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645
12. Fukuoka M, Nitani H, Susuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16
13. Gandara DR, Wold H, Perez EA, Deisseroth AB, Doroshow J, Meyers F, McWhirter K, Hannigan J, De Gregorio MW (1989) Cisplatin dose intensity in non-small-cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst 81:790
14. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg SM, Braun TJ, Natale RB, Balcerzak SP (1993) Evaluation of cisplatin intensity of metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 11:873
15. Gatzemeier U, Heckmayr M, Neuhauss R, Hossfeld D, Achterrath W, Lanaz L (1990) Phase II studies with carboplatin in non-small-cell lung cancer. Semin Oncol 17:25
16. Gore ME, Calvert AH, Smith IE (1986) High-dose carboplatin in patients with lung cancer: a phase I study. Proc Am Soc Clin Oncol 5:179 (abstract)
17. Hainsworth JD, Thompson DS, Greco FA (1995) Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13:1609
18. Ihde DC (1992) Review article: chemotherapy of lung cancer. N Engl J Med 327:1434
19. Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M, DeVore RF III (1996) Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 14:2054
20. Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert PO, Richez M, Ravez P, Vandermoten G, Thiriaux J, Cordier R, Finet C, Berchier MC, Sergysels R, Mommen P, Paesmans M (1990) A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 8:1556
21. Kramer BS, Birch R, Greco A, Prestridge K, DiSimone P, Omura G (1988) Randomized phase II evaluation of iproplatin and carboplatin in lung cancer: a Southeastern Cancer Study Group trial. Am J Clin Oncol 11:643
22. Kris MG, Gralla RJ, Potanovich LM (1991) Long term survival analysis of stage III and IV non-small-cell lung cancer patients (PTS) treated with edetrexate (ETX, 10-EDAM). Lung Cancer 7[Suppl]:111 (abstract)
23. Le Chevalier T, Brisgand D, Douillard J, Pujol J-L, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360
24. Le Chevalier T, Belli L, Monnier A, Sun XC, Douillard JY, Ibrahim N, Soulas F, Bérille (1995) Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer: an interim analysis. Proc Am Soc Clin Oncol 14:350 (abstract)
25. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF (1995) Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 13:1860
26. Lilenbaum R, Green M (1993) Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 11:1391
27. Lilenbaum RC, Green MR (1994) Multimodality therapy for non-small-cell lung cancer. Oncology 8:25
28. Morton RF, Jett JR, McGinnis WL, Earle JD, Therneau TM, Krook JE, Elliott TE, Mailliard JA, Nelimark RA, Maksymiuk AW, Drummond RG, Laurie JA, Kugler JW, Anderson RT (1991) Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small-cell lung cancer: a randomized, phase III trial. Ann Intern Med 115:681
29. Murphy WK, Fosselia FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, Krakoff IH, Hone WK (1993) Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85:384
30. Pastran Z, Le Chevalier T, Baldeyrou P, Spielmann M, Arriagada R, Droz J-P, Rouesse J (1988) Phase II study of high dose ifosfamide plus mesna in inoperable non-small-cell lung carcino3 ma. Eur J Cancer Clin Oncol 24:1073
31. Perez-Soler R, Fossella F, Glisson B, Lee J, Murphy W, Shin D, Kemp B, Lee J, Kane J, Robinson R, Lippman S, Kurie J, Huber M, Raber M, Hong W (1996) Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14:503
32. Rapp E, Pater JL, Willan A, Cannier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF, Hill DP (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633
33. Rosell R, Gómez-Codina J, Camps C, Maestre J, Padille J, Cantó, Mate JL, Li S, Roig J, Olazábal A, Canela M, Ariza A, Skácel Z, Morera-Prat J, Abad A (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153
34. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, Khingra H, De Caro L, Chasen M, McGavran M, Atkinson EN, Hone WK (1994) A randomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86:673
35. Rowinsky EK, Sartorious SE, Bowling MK, Wagner JW, Ettinger DS (1995) Paclitaxel on a 3-hour schedule and carboplatin in non small-cell lung cancer: use of maximally tolerated and clinically relevant single agent doses in combination is feasible. Proc Am Soc Clin Oncol 14:354 (abstract)
36. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S (1986) A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4:14
37. Schaake-Koning C, Van Den Bogaert W, Dalesio O, Festen J, Hoogenhout J, Houtte P van, Kirkpatrick A, Koolen M, Meat B, Nijs A, Renaud A, Rodrigus P, Schuster-Uitterhoeve L, Sculier J-P, Zandwijk N van, Bartelink H (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524
38. Shea T, Graham M, Bernard S, Steagall A, Wiley J, Serody J, Johnston C, Brecher M, Bentley S, Van Le L, Fowler W (1995) Multiple cycles of high dose paclitaxel plus escalating doses of carboplatin with G-CSF (filgrastim) and peripheral blood stem cell (PBSC) support. Proc Am Soc Clin Oncol 14:478 (abstract)
39. 38a. Shea TC, Mason JR, Storniolo AM, Newton B, Breslin M, Mullen M, Ward DM, Miller L, Christian M, Taetle R (1992) Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage, colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 10:464-473
40. Smith TJ, Hillner BE, Neighbors DM, McSorley PA, Le Chevalier T (1995) Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 13:2166
41. Tester W, Cohn J, Desai A, Reardon D, Cohen M (1995) Phase II study of short infusion paclitaxel in patients with stage IV non-small-cell lung cancer (abstract). Proc Am Soc Clin Oncol 14:382
42. Vafai D, Israel V, Zarefsky S, Natale RB (1995) Phase I/II trial of combination carboplatin and taxol in non-small-cell lung cancer. Proc Am Soc Clin Oncol 14:352 (abstract)
43. Woods RL, Williams CJ, Levi J, Page J, Bell D, Byrne M, Kerestes ZL (1990) A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small-cell lung cancer. Br J Cancer 61:608
44. Yokoyama A, Furuse K, Niitani H, members of the Navelbine Study Group (1992) Multi-institutional phase II study of navelbine (vinorelbine) in non-small-cell lung cancer. Proc Am Soc Clin Oncol 11:287 (abstract)